These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1692 related items for PubMed ID: 25468321

  • 1. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, Pogliani EM, Pioltelli PE.
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [Abstract] [Full Text] [Related]

  • 2. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.
    Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
    [Abstract] [Full Text] [Related]

  • 3. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C.
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
    Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY.
    Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479
    [Abstract] [Full Text] [Related]

  • 6. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
    Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN.
    Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
    [Abstract] [Full Text] [Related]

  • 7. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.
    Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ.
    PLoS One; 2012 Dec; 7(7):e41658. PubMed ID: 22911837
    [Abstract] [Full Text] [Related]

  • 8. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y.
    Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
    [Abstract] [Full Text] [Related]

  • 9. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
    Tomita N, Takasaki H, Fujisawa S, Miyashita K, Ogusa E, Kishimoto K, Matsuura S, Sakai R, Koharazawa H, Yamamoto W, Fujimaki K, Fujita H, Ishii Y, Taguchi J, Kuwabara H, Motomura S, Ishigatsubo Y.
    J Clin Exp Hematop; 2013 Oct; 53(2):121-5. PubMed ID: 23995108
    [Abstract] [Full Text] [Related]

  • 10. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M.
    Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
    [Abstract] [Full Text] [Related]

  • 11. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
    Yhim HY, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY.
    Int J Cancer; 2012 Jul 01; 131(1):235-43. PubMed ID: 21823120
    [Abstract] [Full Text] [Related]

  • 12. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.
    Int J Oncol; 2011 Dec 01; 39(6):1413-20. PubMed ID: 21874232
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW, Ryu JS, Kim SJ, Kim WS, Yoon DH, Suh C.
    Oncotarget; 2016 Nov 22; 7(47):76934-76943. PubMed ID: 27764777
    [Abstract] [Full Text] [Related]

  • 14. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, Vose J, Lenz G, Staudt L, Chan W, Weisenburger DD.
    Am J Clin Pathol; 2011 Jan 22; 135(1):54-61. PubMed ID: 21173124
    [Abstract] [Full Text] [Related]

  • 15. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M, Augustin F, Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle H, Schreieck S, Schnallinger M, Fiegl M.
    Anticancer Res; 2014 May 22; 34(5):2559-64. PubMed ID: 24778077
    [Abstract] [Full Text] [Related]

  • 16. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T, Shimada K, Yamamoto K, Hirooka Y, Niwa Y, Sugiura I, Kitamura K, Kosugi H, Kinoshita T, Goto H, Nakamura S.
    Ann Hematol; 2012 Mar 22; 91(3):383-90. PubMed ID: 21822617
    [Abstract] [Full Text] [Related]

  • 17. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC, Gamboa-Alonso CM, Vázquez-Mellado de Larracoechea A, Rodríguez-Martínez M, Gutiérrez-Aguirre CH, Marfil-Rivera LJ, Gómez-Almaguer D.
    Arch Med Res; 2015 Aug 22; 46(6):454-61. PubMed ID: 26235285
    [Abstract] [Full Text] [Related]

  • 18. [Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma].
    Oliver C, Guillermo C, Martínez P, Díaz L.
    Rev Med Chil; 2013 Jul 22; 141(7):844-52. PubMed ID: 24356732
    [Abstract] [Full Text] [Related]

  • 19. Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.
    Zhou S, Xu L, Ma Y, Tang L, Zhang Y, Shi Y, Sun L, Chen Y, Liang B, Zhou Y, Yu K, Shen J.
    Oncotarget; 2017 Mar 21; 8(12):19556-19565. PubMed ID: 28107187
    [Abstract] [Full Text] [Related]

  • 20. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.
    Am J Hematol; 2015 Sep 21; 90(9):778-83. PubMed ID: 26044261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 85.